Get started
Rhythm Pharmaceuticals, Inc.Rhythm Pharmaceuticals, Inc.Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

RYTM trade ideas

RYTM Biotech Penny Anti-Obesity LONGRYTM did a 120% run in November and December and then pivoted to start the year. It competes in the anti-obesity drug space which is all the rage right now and has snack food manufactures freaking out. The retrace was a shallow one in a sign of strength finding support at the 0.382 retracement level and then pivoting into a reversal in the past week. The dual TF RSI shows the resurgence of bullish momentum. Earnings were okay, but not great. An FDA approval to add to the mix of meds and lower their price in the competition may send RHYTHM into launch mode. RYTM did 10% today such is the life of highly volatile penny stocks in what is considered to be the likely hottest sector of the year. I will look toward OTM call options for February 16th presently priced at about $200 per contract and a couple of shares shorted to provide some hedging. Looking for 100% in 2-3 weeks. Will close 1/2 the position a few days before upcoming earnings.
NASDAQ:RYTMLong
by AwesomeAvani
1
RYTM- More downside to come? NASDAQ:RYTM This stock seems to be following a textbook Wyckoff market cycle and appears to be transitioning from markup to markdown. Mid May was the beginning of a multi week base building/accumulation On June 16-17 we can see the "spring" that preceded a huge markup in prices. After that a sharp rally in prices into the $11-$13 range that formed a pennant continuation pattern, then earnings came and boom it shot into a preliminary supply area(PSY) followed by a 35% move from $20 to a day high of 27.21 buying climax (BC). Last weeks UTAD failed rally/ blowoff top on high volume gave way to this weeks feeble rally with red hourly candles on high volume, showing that big players are dumping shares onto greedy retail traders, who are providing liquidity. A crown has formed and todays large red candles punched down into lower prices with a high probability of lower prices in the future. The last points of supply (LPSY) seem inevitable. Given the context of Julys " bad news is good news" rallies in many stocks this was one that wasn't left behind. It appreciated 10x from its June low! This stock is slowly dripping down into a low volume area. Once there, it might just liquidate dramatically downside. Will be on the lookout next week for any relief rallies that will provide low risk short entries. Ultimate target would be the $17.04 .5 fib or $13.76 .618 fib range, potentially lower considering the current state of the market. Please like, comment or follow :)
NASDAQ:RYTMShort
by robbtronic
$RYTM Next Target PTs 5.50-6.50 and higherRhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
NASDAQ:RYTMLong
by BADQOMOCAWGOWLD
Big Week Coming For $RYTMRYTM releases phase 3 trial data for their drug, Setmelanotide , on the 20th. Also, their chart looks very bullish. They recently broke out of their downtrend, which as you can see from the past is an extremely bullish sign. They also appear to be at the bottom of their current channel. Another bullish sign is the low volume. This means that good news could make huge moves for the stock. I anticipate at least a 13% run-up this week, and if the news is good, the stock could surge anywhere from 20-80%. I would recommend selling at the market open on Monday because bios are generally unstable during the day. However, because biotechs are very dependent on good news, my strategy for bios is to buy a certain amount and play the anticipation, then sell 1/2-3/4 of my shares on the last trading day before the press release. For this one I'm planning on only selling half of my shares on Friday, considering their past clinical trial results for this drug have been good and it is in phase 3. Like and follow if you want to see more like this :) Good Luck!
NASDAQ:RYTMLong
by Investor4321
1
RYTM - Good point to buy$RYTM - the stock has approached the lower boundary of the uptrend starting on 3/16/20. Support levels other than the trend line are: - two VWAP lines: 1st from the minimum value (3/16/20) and 2nd from the IPO date. - 200D EMA - Support zone, which has already been repeatedly tested. MACD indicator is in the negative zone and has crossed the signal line. Presentations at the Annual Meeting and Expo of the Endocrine Society (ENDO 2021) on March 20-23 might be a potential driver in the near term. The average target for the stock is $46.25, the current price is 26.09. Upside 77%. According to Form 8-K, the company has enough equity until the second half of 2023. Nearest growth targets are $32.2, $36.2. Stop below $24.6. This point of view is my personal view and is not invest recommendation.
NASDAQ:RYTMLong
by kovpups
Rhythm: therapies for the treatment of rare genetic disordersHi guys, Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity. Long: LMT 1- 19.9$ (20 % of the planned investment amount) LMT 2- 19.21$ (40 % of the planned investment amount) LMT 3- 18,31$ (40 % of the planned investment amount) TP: 31.4$ Comments and likes are greatly appreciated. I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions and this is not a call for investment. I am not receiving compensation for it . I have no business relationship with any company whose stock is mentioned in this article.
NASDAQ:RYTMLong
by UnknownUnicorn4608205